BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tang NP, Wu YM, Wang B, Ma J. Systematic review and meta-analysis of the association between P53 codon 72 polymorphism and colorectal cancer. Eur J Surg Oncol. 2010;36:431-438. [PMID: 20363586 DOI: 10.1016/j.ejso.2010.03.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Shen CC, Cheng WY, Lee CH, Dai XJ, Chiao MT, Liang YJ, Hsieh WY, Mao TF, Lin GS, Chen SR, Liu BS, Chen JP. Both p53 codon 72 Arg/Arg and pro/Arg genotypes in glioblastoma multiforme are associated with a better prognosis in bevacizumab treatment. BMC Cancer 2020;20:709. [PMID: 32727419 DOI: 10.1186/s12885-020-07210-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Elshazli RM, Toraih EA, Elgaml A, Kandil E, Fawzy MS. Genetic polymorphisms of TP53 (rs1042522) and MDM2 (rs2279744) and colorectal cancer risk: An updated meta-analysis based on 59 case-control studies. Gene 2020;734:144391. [PMID: 32001373 DOI: 10.1016/j.gene.2020.144391] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
3 Zhang Y, Zhang D, Zhao L, Sun L, Dong Q, Cheng L, Cheng R. Association between p53 Arg72Pro polymorphism and colorectal cancer risk in Asian population: a meta-analysis. Current Problems in Cancer 2018;42:582-92. [DOI: 10.1016/j.currproblcancer.2018.08.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ma S, Lei Y, Zhang L, Wang J. Effects of zerumbone on proliferation and apoptosis of esophageal cancer cells and on P53 and Bcl-2 expression levels. Oncol Lett 2018;16:4379-83. [PMID: 30197671 DOI: 10.3892/ol.2018.9184] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
5 Tian X, Dai S, Sun J, Jiang S, Jiang Y. The association between the TP53 Arg72Pro polymorphism and colorectal cancer: An updated meta-analysis based on 32 studies. Oncotarget 2017;8:1156-65. [PMID: 27901479 DOI: 10.18632/oncotarget.13589] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
6 Hedayatizadeh-Omran A, Alizadeh-Navaei R, Janbabaei G, Omrani-Nava V, Hasheminasab Y, Amjadi O, Tehrani M. Association of P53 gene polymorphism with gastric cancer in Northern Iran as a high-risk region. Biomed Rep 2018;8:433-8. [PMID: 29616139 DOI: 10.3892/br.2018.1070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
7 Yagnik G, Jahangiri A, Chen R, Wagner JR, Aghi MK. Role of a p53 polymorphism in the development of nonfunctional pituitary adenomas. Mol Cell Endocrinol 2017;446:81-90. [PMID: 28214592 DOI: 10.1016/j.mce.2017.02.017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
8 Kamiza AB, Hsieh LL, Tang R, Chien HT, Lai CH, Chiu LL, Lo TP, Hung KY, You JF, Wang WC, Hsiung CA, Yeh CC. TP53 Polymorphisms and Colorectal Cancer Risk in Patients with Lynch Syndrome in Taiwan: A Retrospective Cohort Study. PLoS One 2016;11:e0167354. [PMID: 27907203 DOI: 10.1371/journal.pone.0167354] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
9 Mahmood S, Sivoňová M, Matáková T, Dobrota D, Wsólová L, Dzian A, Mištuna D. Association of EGF and p53 gene polymorphisms and colorectal cancer risk in the Slovak population. Open Medicine 2014;9:405-16. [DOI: 10.2478/s11536-013-0300-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Polakova Vymetalkova V, Vannucci L, Korenkova V, Prochazka P, Slyskova J, Vodickova L, Rusnakova V, Bielik L, Burocziova M, Rossmann P, Vodicka P. Evaluation of tumor suppressor gene expressions and aberrant methylation in the colon of cancer-induced rats: a pilot study. Mol Biol Rep 2013;40:5921-9. [PMID: 24065530 DOI: 10.1007/s11033-013-2699-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
11 Wang S, Chen L, Zhao Q, Rong H, Wang M, Gong W, Zhou J, Wu D, Zhang Z. Effect of TP53 codon 72 and MDM2 SNP309 polymorphisms on survival of gastric cancer among patients who receiving 5-fluorouracil-based postoperative adjuvant chemotherapy. Cancer Chemother Pharmacol. 2013;71:1073-1082. [PMID: 23423487 DOI: 10.1007/s00280-013-2103-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
12 Sagne C, Marcel V, Amadou A, Hainaut P, Olivier M, Hall J. A meta-analysis of cancer risk associated with the TP53 intron 3 duplication polymorphism (rs17878362): geographic and tumor-specific effects. Cell Death Dis 2013;4:e492. [PMID: 23412385 DOI: 10.1038/cddis.2013.24] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
13 Theodoratou E, Montazeri Z, Hawken S, Allum GC, Gong J, Tait V, Kirac I, Tazari M, Farrington SM, Demarsh A, Zgaga L, Landry D, Benson HE, Read SH, Rudan I, Tenesa A, Dunlop MG, Campbell H, Little J. Systematic Meta-Analyses and Field Synopsis of Genetic Association Studies in Colorectal Cancer. JNCI Journal of the National Cancer Institute 2012;104:1433-57. [DOI: 10.1093/jnci/djs369] [Cited by in Crossref: 79] [Cited by in F6Publishing: 85] [Article Influence: 7.9] [Reference Citation Analysis]
14 Liu KJ, Qi HZ, Yao HL, Lei SL, Lei ZD, Li TG, Zhao H. An updated meta-analysis of the p53 codon 72 polymorphism and gastric cancer risk. Mol Biol Rep. 2012;39:8265-8275. [PMID: 22707142 DOI: 10.1007/s11033-012-1674-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
15 Liu L, Wang K, Zhu ZM, Shao JH. Associations between P53 Arg72Pro and development of digestive tract cancers: a meta-analysis. Arch Med Res 2011;42:60-9. [PMID: 21376265 DOI: 10.1016/j.arcmed.2011.01.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
16 Zhang R, Chen W, Zhang W, Jiang Q, Liu C, Lin Y, Hu Z, Yu S, Xu G. Genetic Polymorphisms of p 53 Codon 72 and Bladder Cancer Susceptibility: A Hospital-Based Case–Control Study. Genetic Testing and Molecular Biomarkers 2011;15:337-41. [DOI: 10.1089/gtmb.2010.0230] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
17 Liu W, Yu YH, Ouyang XN, Wang L, Wu YM, Chen J, Xiong XS. Clinical significance of P53 and Ki67 expression in gastric cancer. Shijie Huaren Xiaohua Zazhi 2011; 19(4): 367-373 [DOI: 10.11569/wcjd.v19.i4.367] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
18 Sergentanis TN, Economopoulos KP. Re: Jiang et al.: Meta-analysis of Association Between TP53 Arg72Pro Polymorphism and Bladder Cancer Risk (Urology 2010;76:765). Urology 2011;77:259-260. [DOI: 10.1016/j.urology.2010.08.061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 Wang JJ, Zheng Y, Sun L, Wang L, Yu PB, Dong JH, Zhang L, Xu J, Shi W, Ren YC. TP53 codon 72 polymorphism and colorectal cancer susceptibility: a meta-analysis. Mol Biol Rep 2011;38:4847-53. [PMID: 21140221 DOI: 10.1007/s11033-010-0619-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
20 Economopoulos K, Sergentanis T. Methodological remarks concerning the recent meta-analysis on p53 codon 72 polymorphism and colorectal cancer risk. European Journal of Surgical Oncology (EJSO) 2010;36:1225-1226. [DOI: 10.1016/j.ejso.2010.09.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]